Frontlight ResearchEarly access
TerminatedNo phase
Study of the Braive Growth Modulation System for Progressive Pediatric Scoliosis
Key facts
- Who runs it
- Medtronic Spinal and Biologics
- Where
- Rochester, United StatesSee the siteAlso in 2 other countries, 3 sites
- Trial code
- Status
- Terminated
- People taking part
- 10 people enrolled
- Started
- 12 Aug 2021
- Ended
- 14 Jan 2026
- Type of study
- Interventional
- Treatments tested
- Braive™ Growth Modulation System (Braive™ GMS)
- Record updated
- 28 October 2026
- Why it stopped
- The decision to early terminate the study was taken based on the achievement of all primary endpoints at 24-month for every active subjects. In addition, there are currently no plans to use the collected data to seek regulatory approval.
Who can take part
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 27 criteriaShow less
Who can take part
- A subject must meet all of the following inclusion criteria to participate in this study:
- Has a diagnosis of juvenile or adolescent idiopathic scoliosis
- Is skeletally immature with a Sanders Score of ≥2 to ≤5
- Has failed conservative care as per investigator's assessment
- Has a main thoracic Cobb angle between 30 and 60 degrees
- Has a Lenke Classification of 1A, 1B, or 1C
- Has kyphosis ≤ 40 degrees with a sagittal thoracic modifier N or negative
- Informed Consent Form/Assent and Authorization to Use and Disclose Health Information (if applicable) have been signed by Parent/legal guardian and/or patient/participant per local requirement
Who cannot take part
- Has undergone previous spinal fusion procedure(s) at the affected levels
- Has had prior ipsilateral or contralateral chest surgery
- Concurrent participation in another clinical study that may add additional safety risks and/or confound study results
- Has an associated syndrome
- Has a history of malignant hyperthermia
- Has an active or significant risk of infection (immunocompromised)
- Has a suspected or documented allergy or intolerance to implant materials
- Has a major psychiatric disorder / history of drug abuse that would interfere with the subject's ability to comply with study instructions or might confound the study interpretation as per investigator's assessment (DSM-5 can be used as a reference)
- Has severe chronic lung disease (e.g., asthma, bronchiectasis)
- A subject will be excluded from participating in this study for any of the following reasons:
- Is pregnant or plans to become pregnant within the first 24-months of the study
- Has a curve that requires instrumentation below L1
- Has spinal MRI abnormalities (e.g., CHIARI malformation, Syrinx greater than 4mm, tethered cord)
- Has any type of non-idiopathic scoliosis
- Has a left-sided curve
- Has inadequate tissue coverage over the operative site as per investigator's assessment
- Is a ward of the court/state
- Has poor bone quality, as determined by the investigator, that may limit anterior fixation
- Is unwilling or unable to return for follow-up visits and/or follow intra-operative and/or postoperative instructions
Where in United States
Also in 2 other countries, 3 sites
- Mayo ClinicRochester, United States
About the trial
What the trial wants to find out
The purpose of this study was to establish probable benefits and evaluate the safety and preliminary effectiveness of the Braive™ GMS when used in the treatment of pediatric progressive scoliosis.
The group in the trial
- Braive™ Growth Modulation System (Braive™ GMS)Treatment being tested
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Prospective, Multi-Center Study of the Braive™ Growth Modulation System When Used in the Treatment of Pediatric Patients Diagnosed With Juvenile or Adolescent Idiopathic Scoliosis
- Record updated
- 28 October 2026